TG Therapeutics Inc. (TGTX) Jumps 11.19% on January 20

Equities Staff |

TG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Wednesday January 20 as the stock popped 11.19% to $9.64, representing a gain of $0.97 per share. Some 461,062 shares traded hands on 3,302 trades, compared with an average daily volume of 605,972 shares out of a total float of 52.52 million. The stock opened at $8.50 and traded with an intraday range of $9.66 to $8.43.

After today's gains, TG Therapeutics Inc. reached a market cap of $506.29 million. TG Therapeutics Inc. has had a trading range between $20.00 and $7.68 over the last year, and it had a 50-day SMA of $11.88 and a 200-day SMA of $14.16.

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.

TG Therapeutics Inc. is based out of New York, NY and has some 30 employees. Its CEO is Michael S. Weiss.

For a complete fundamental analysis analysis of TG Therapeutics Inc., check out’s Stock Valuation Analysis report for TGTX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…